Millennium Pharmaceuticals, Inc. (MLNM) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: icanpickem who started this subject	12/16/2002 3:53:21 AM
From: Doc Bones	Read Replies (1) of 3044

A favorable mention in Barrons. Nothing new, I think, but Barrons is sometimes good for a gap up at the open on Monday. Doc ----- <snip> At the same medical conference, sponsored by the American Society of Hematology, researchers reported good news on a cancer treatment developed by Millennium Pharmaceuticals. Patients whose multiple myeloma blood cancer had resisted chemotherapy showed impressive response to the company's drug Velcade. The biotech drug seems to have eliminated the stubborn cancer in a few patients, and forced cancer into retreat in one-third of the study's 54 patients. Cancer stopped progressing in almost 60% of patients. David Shenkein, Millennium's vice president for cancer studies, says that early next year the firm will seek FDA approval of Velcade for chemo-resistant myeloma. In the lab, Millennium is testing Velcade against solid tumors, too. Shenkein says investors will learn more at the spring meeting of the American Society of Clinical Oncology As with Avigen, investors cashed in on Millennium's news, dropping the shares to $8.91 by week's end from about $11.25. <snip> online.wsj.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next